Heart Failure Research Review: Issue 78, with commentary by Dr Mark Nolan

In this edition:

–  Dapagliflozin in HF with mildly reduced/preserved EF: HF events
–  AF ablation for HFPEF
–  Uptitrating treatment after HF hospitalisation across LVEF spectrum
–  ARNI for mildly reduced/preserved EF and worsening HF
–   HF hospitalisations with tablet-based telemonitoring added to phone management
–  SGLT-2 inhibitors vs. sitagliptin in HF and type 2 diabetes
–  Importance of cystatin C in estimating GFR
–  Skeletal muscle mitochondrial respiration and exercise intolerance in HFPEF
–  Autonomic regulation therapy in chronic HF with preserved/mildly reduced EF
–  HF care quality and outcomes at US hospitals with high proportions of Black patients

Download Heart Failure Research Review Issue 78, with commentary by Dr Mark Nolan